Evotec SE (NASDAQ:EVO - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $3.41, but opened at $3.29. Evotec shares last traded at $3.29, with a volume of 4,840 shares trading hands.
Evotec Stock Performance
The business has a 50 day moving average of $4.07 and a 200-day moving average of $4.10. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09.
Institutional Investors Weigh In On Evotec
Institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP increased its holdings in Evotec by 29.7% during the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock worth $9,616,000 after acquiring an additional 602,858 shares during the period. DCF Advisers LLC increased its holdings in shares of Evotec by 5.9% in the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after purchasing an additional 12,816 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Evotec in the fourth quarter worth $27,000. Bank of America Corp DE boosted its stake in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after buying an additional 9,289 shares during the period. Finally, Lighthouse Investment Partners LLC purchased a new position in Evotec during the fourth quarter worth about $166,000. 5.81% of the stock is owned by hedge funds and other institutional investors.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
